BSR and BHPR guideline for the management of adults with ANCA-associated vasculitis.

BSR and BHPR guideline for the management of adults with ANCA-associated vasculitis.

Opis bibliograficzny
Główni autorzy:	Ntatsaki, E, Carruthers, D, Chakravarty, K, D'Cruz, D, Harper, L, Jayne, D, Luqmani, R, Mills, J, Mooney, J, Venning, M, Watts, R
Format:	Journal article
Język:	English
Wydane:	2014

Podobne zapisy

BSR and BHPR guidelines for the management of adults with ANCA associated vasculitis.
od: Lapraik, C, i wsp.
Wydane: (2007)

BSR and BHPR guidelines on the use of rituximab in rheumatoid arthritis.
od: Bukhari, M, i wsp.
Wydane: (2011)

BSR and BHPR rheumatoid arthritis guidelines on safety of anti-TNF therapies.
od: Ding, T, i wsp.
Wydane: (2010)

BSR and BHPR rheumatoid arthritis guidelines on eligibility criteria for the first biological therapy.
od: Deighton, C, i wsp.
Wydane: (2010)

BSR and BHPR rheumatoid arthritis guidelines on eligibility criteria for the first biological therapy.
od: Deighton, C, i wsp.
Wydane: (2010)

BSR and BHPR rheumatoid arthritis guidelines on eligibility criteria for the first biological therapy (vol 49, pg 1197, 2010)
od: Deighton, C, i wsp.
Wydane: (2010)

Cardiovascular outcomes in ANCA associated vasculitis
od: Mukhtyar, C, i wsp.
Wydane: (2008)

Diagnosis and management of ANCA associated vasculitis.
od: Berden, A, i wsp.
Wydane: (2012)

Predictors of renal involvement in ANCA associated vasculitis
od: Kronbichler, A, i wsp.
Wydane: (2018)

THE PROGNOSTIC VALUE OF THE BIRMINGHAM VASCULITIS ACTIVITY SCORE AND THE VASCULITIS DAMAGE INDEX IN ANCA-ASSOCIATED VASCULITIS
od: Suppiah, R, i wsp.
Wydane: (2011)

Explaining fatigue in ANCA-associated vasculitis
od: Basu, N, i wsp.
Wydane: (2013)

Cutaneous manifestations of ANCA-associated vasculitis
od: Chiesafuxench, Z, i wsp.
Wydane: (2016)

Markers for work disability in ANCA-associated vasculitis
od: Basu, N, i wsp.
Wydane: (2013)

Explaining fatigue in ANCA-associated vasculitis.
od: Basu, N, i wsp.
Wydane: (2013)

Outcome measures in ANCA-associated vasculitis.
od: Suppiah, R, i wsp.
Wydane: (2010)

EULAR/ERA-EDTA RECOMMENDATIONS FOR THE MANAGEMENT OF ANCA-ASSOCIATED VASCULITIS
od: Yates, M, i wsp.
Wydane: (2016)

Cardiovascular disease incidence and risk factors in ANCA-associated primary systemic vasculitis (AASV)
od: Salisbury, E, i wsp.
Wydane: (2003)

Long-term survival of ANCA-associated vasculitis
od: Flossmann, O, i wsp.
Wydane: (2009)

A multi-centre randomised trial of cyclophosphamide versus azathioprine during remission in ANCA-associated systemic vasculitis (Cycazarem).
od: Luqmani, R, i wsp.
Wydane: (1999)

Damage assessment in ANCA-associated vasculitis.
od: Bhamra, K, i wsp.
Wydane: (2012)

Maintenance of clinical remission in ANCA-associated vasculitis.
od: Luqmani, R
Wydane: (2013)

INCIDENCE OF NON-FATAL CLINICAL CORONARY EVENTS IN PRIMARY ANCA-ASSOCIATED SYSTEMIC VASCULITIS (AASV)
od: Salisbury, E, i wsp.
Wydane: (2003)

CARDIOVASCULAR AND CEREBROVASCULAR DISEASE INCIDENCE AND RISK FACTORS IN ANCA-ASSOCIATED PRIMARY SYSTEMIC VASCULITIS (AASV)
od: Salisbury, E, i wsp.
Wydane: (2004)

EULAR recommendations for conducting clinical studies and/or clinical trials in ANCA-associated vasculitis
od: Luqmani, R, i wsp.
Wydane: (2007)

CONTEXTUALISING QUALITY OF LIFE IN ANCA ASSOCIATED VASCULITIS (AAV)
od: Basu, N, i wsp.
Wydane: (2012)

The characterisation and determinants of quality of life in ANCA associated vasculitis
od: Basu, N, i wsp.
Wydane: (2014)

Comparison of disease activity measures for ANCA-associated vasculitis.
od: Merkel, P, i wsp.
Wydane: (2004)

Peripheral neuropathy in ANCA-associated vasculitis: outcomes from the European Vasculitis Study Group trials
od: Suppiah, R, i wsp.
Wydane: (2011)

Incidence of non-fatal clinical coronary events in primary ANCA-associated systemic vasculitis (aasv)
od: Salisbury, E, i wsp.
Wydane: (2003)

THE DEMOGRAPHY OF ANCA ASSOCIATED VASCULITIS: 735 PATIENTS RECRUITED AT DIAGNOSIS TO SIX EUROPEAN VASCULITIS STUDY GROUP TRIALS
od: Yew, S, i wsp.
Wydane: (2012)

OP0053 Eular/ERA-EDTA Recommendations for The Management of Anca-Associated Vasculitis
od: Yates, M, i wsp.
Wydane: (2016)

The characterisation and determinants of quality of life in ANCA associated vasculitis.
od: Basu, N, i wsp.
Wydane: (2014)

Opinion: Maintenance of clinical remission in ANCA-associated vasculitis
od: Luqmani, R
Wydane: (2013)

Determinants of Poor Quality of Life in ANCA Associated Vasculitis (AAV).
od: Basu, N, i wsp.
Wydane: (2012)

EULAR/ERA-EDTA recommendations for the management of ANCA-associated vasculitis
od: Yates, M, i wsp.
Wydane: (2016)

Does a gating policy for ANCA overlook patients with ANCA associated vasculitis? An audit of 263 patients.
od: Arnold, D, i wsp.
Wydane: (2010)

Long-term patient survival in ANCA-associated vasculitis
od: Flossmann, O, i wsp.
Wydane: (2011)

Long-term patient survival in ANCA-associated vasculitis.
od: Flossmann, O, i wsp.
Wydane: (2011)

Global ethnic and geographic idfferences in the clinical features of ANCA-associated vasculitis
od: Pearce, F, i wsp.
Wydane: (2016)

Rituximab versus cyclophosphamide in ANCA-associated renal vasculitis.
od: Jones, R, i wsp.
Wydane: (2010)